Show heart failure rates in diabetes trials: experts

Heart failure is almost universally ignored in large-scale diabetes trials even though some glucose-lowering drugs unequivocally raise the risk, experts report this week in the Lancet.

Although regulatory bodies require proof of cardiovascular safety in all new glucose-lowering drug trials, they do not specify hospital admissions for heart failure even though this is a common complication of diabetes, the